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Abstract
Cationic liposomes may be valuable for the delivery of anti-sense oligonucleotides, ribozymes, and therapeutic genes into human
immunodeficiency virus type 1 (HIV-1)-infected and uninfected cells. We evaluated the toxicity of three cationic liposomal preparations,
Lipofectamine, Lipofectin, and 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethylammonium bromide (DMRIE) reagent, to HIV-infected
and uninfected cells. Monocyte/macrophages were infected with HIV-1BaL and treated with liposomes in medium containing 20% fetal
bovine serum (FBS) for 4 h or 24 h at 37°C. Uninfected monocytic THP-1 cells and chronically infected THP-1/HIV-ImB cells were
treated with phorbol 12-myristate 13-acetate (PMA) and exposed to liposomes in the presence of 10% FBS. Toxicity was evaluated by the
Alamar Blue assay and viral p24 production. The toxic effect of cationic liposomes was very limited with uninfected cells, although
concentrations of liposomes that were not toxic within a few days of treatment could cause toxicity at later times. In HIV-I Bae-infected
macrophages, Lipofectamine (up to 8 ~M) and Lipofectin (up to 40 txM) were not toxic after a 4-h treatment, while DMRIE reagent at
40 txM was toxic. While a 4-h treatment of THP-1/HIV-lum cells with the cationic liposomes was not toxic, even up to 14 days
post-treatment, all three cationic liposomes were toxic to cells at the highest concentration tested after a 24-h treatment. Similar results
were obtained with the Alamar Blue assay, Trypan Blue exclusion and a method that enumerates nuclei. Infected cells with relatively high
overall viability could be impaired in their ability to produce virions, indicating that virus production appears to be more sensitive to
treatment with the cationic liposomes than cell viability. Our results indicate that HIV-infected cells are more susceptible than uninfected
cells to killing by cationic liposomes. The molecular basis of this differential effect is unknown; it is proposed that alterations in cellular
membranes during virus budding cause enhanced interactions between cationic liposomes and cellular membranes.
Keywords: HIV-1; Cationic liposome; Cytotoxicity; Macrophage; (Human)

1. Introduction
Cationic liposomes provide a simple and efficient means
of introducing D N A and other polynucleotides into eukaryotic cells. Small unilamellar liposomes composed of
cationic lipids spontaneously complex with negatively
charged compounds. In most cases transfection becomes
efficient only when liposomes contain the membrane fusion-promoting lipid, dioleoylphosphatidylethanolamine
(DOPE), and the nucleic acid-lipid complexes have a net
positive charge [1,2]. Cationic liposomes have been used to
facilitate delivery of D N A [3-7], m R N A [8], antisense
* Corresponding author. Fax: + 1 415 9296564.
0167-4889/96/$15.00 © 1996 Elsevier Science B.V. All rights reserved
PII S01 67-48 89(96)00033-X

oligonucleotides [9] and proteins [10,11] into living cells.
Unlike viral vectors, liposomes are noninfectious and appear to be non-immunogenic in vivo. They have been
utilized for gene delivery in vivo [1,12-15], and a direct
gene transfer protocol using a liposome-DNA complex has
been approved for injection into solid tumors in patients
[16].
Although many studies have been carried out to improve liposome-mediated transfection (lipofection), these
techniques suffer from variable transfection efficiency. The
composition of the cationic liposomes, the lipid-DNA ratio, overall lipid concentration, the cell type and the density of the cell culture are critical for efficient transfection
[2,3,17]. Since the first report o f transfection by the cationic
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lipid reagent, Lipofectin [3], several different kinds of
cationic lipids have been developed, including quaternary
ammonium detergents, cationic derivatives of cholesterol
and diacyl glycerol, and lipid derivatives of polyamines
[1,181.
Cationic liposomes and DNA-liposome complexes may
enter the cells by membrane fusion or spontaneous endocytosis, but the precise mechanism of their interaction with
the cell membrane has not been elucidated. Liposomes
composed of N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium (DOTMA), the cationic component of Lipofectin, were found to undergo lipid mixing with lymphocytic A3.01 and Raji cells in serum-free medium. However, lipid mixing was inhibited by the presence of serum,
although the liposomes could still bind to the cell membrane [19]. Cationic liposomes can undergo fusion with
negatively charged liposomes and erythrocyte membranes
[4,20,21]. The diffuse pattern of fluorescence in cell membranes following incubation with DNA-complexed
DOTMA/DOPE liposomes has been interpreted as reflecting the fusion of the lipid DNA complex with the plasma
membrane of the cells, resulting in delivery of the exogenous DNA into the cytoplasm [3,4]. On the other hand, the
fusion activity of certain cationic liposomes (measured by
their ability to fuse with negatively charged liposomes) can
be abolished by preincubation with DNA; nevertheless,
these lipids can mediate efficient uptake of DNA by
cultured cells [22]. In addition, the fusion activities of
different cationic liposomes, in the absence or presence of
DNA, do not correlate with their transfection activities
[22]. It is possible that the majority of DNA-liposome
complexes are taken up through adsorption-mediated endocytosis. Although a recent study has indicated that the
fusion of cationic liposomes with cultured Hep G-2 cells in
phosphate-buffered saline occurs following endocytosis
[23], it is not known whether DNA-liposome complexes
can also undergo fusion after endocytosis, and what the
effect of serum is on this process. Since fusion of the
endocytotic vesicles with lysosomes would lead to degradation of the DNA, the DNA must enter the cytoplasm
before this fusion event for successful transfection to
occur. The endosome membrane may be destabilized by
the cationic lipid,resulting in the release of the intact
DNA-liposome complex into the cytoplasm [22-26]. Very
little is known about the mechanism by which DNA
localizes in the nucleus, except that only a small percentage of the cytoplasmically delivered DNA reaches the
nucleoplasm [4,27]. It is possible that the cationic liposome-DNA complex enters the nucleus as an intact complex [28]. Lipofectin complexes of antisense oligonucleotides also localize in the nucleus, as well as in discrete
structures in the cytoplasm [29].
Cells of monocyte/macrophage lineage can be easily
infected by HIV and are thought to play an important role
in the pathogenesis and progression of HIV-related disease
[30-32]. Large numbers of infected macrophages have
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been found in lymph nodes, liver, spleen, lungs, skin,
brain, and nearly all tissues and organs from infected
subjects [31-33], and chronically infected macrophages are
considered to be a reservoir for HIV in infected individuals. Inhibition of virus production in such cells would
require agents that are effective in inhibiting HIV gene
expression or maturation, or in cleaving viral RNA sequences. These agents may have limited access to the
cytoplasm, and cationic liposomes may be useful for the
delivery of antisense oligodeoxynucleotides, ribozymes or
therapeutic genes into chronically infected macrophages.
As a first step towards the use of such liposomes in
macrophages, we investigated the toxicity of three cationic
liposomal preparations, Lipofectamine, Lipofectin and liposomes composed of DMRIE and DOPE (1 : 1), to human
monocyte-derived macrophages and a differentiated monocytic cell line, THP-1. Since the cationic liposomes would
eventually be used to deliver antiviral agents to HIV-infected cells, we also investigated the toxicity of the liposomes to macrophages infected with the monocytotropic
strain HIV-IBa L, as well as to chronically infected THP1/HIV-1Hm cells. Our results indicate that cationic liposomes have a differential toxicity for HIV-infected cells
under certain conditions. Some of our results have been
presented earlier in preliminary form [35].

2. Materials and methods
2.1. Materials

Lipofectamine Reagent [36] containing the polycationic
lipid 2,3-dioleyloxy-N[2(sperminecarboxamido)ethyl]N,N-dimethyl-l-propanaminium trifluoroacetate (DOSPA)
and the neutral lipid, dioleoylphosphatidylethanolamine
(DOPE) (3:1, w/w), and Lipofectin Reagent [3] containing
the monocationic lipid N-[1-(2,3 dioleyloxy)-propyl]N,N,N-trimethylammonium chloride (DOTMA) and DOPE
(1:1, w / w ) were obtained from Gibco BRL Life Technologies, Inc. (Gaithersburg, MD). DMRIE reagent [37] (a
1:1 ( w / w ) mixture of 1,2-dimyristyloxypropyl-3dimethyl-hydroxyethylammonium bromide (DMRIE) and
DOPE) was synthesized by VICAL, Inc. (San Diego, CA).
Alamar Blue dye was purchased from Alamar Biosciences
Inc. (Sacramento, CA). The enzyme-free, PBS-based, cell
dissociation buffer was obtained from Gibco BRL Life
Technologies, Inc. (Gaithersburg, MD). Triton X-100,
Nonidet P-40 (NP-40) and naphtol blue black (Buffalo
Black NBR), were obtained from Sigma (St. Louis, MO).
2.2. Cells and virus

Monocytes were obtained from HIV seronegative buffy
coats by centrifugation on a Ficoll-Hypaque (Histopaque1077; Sigma, St. Louis, MO) gradient and plastic adherence. Briefly, mononuclear cells separated by centrifuga-
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tion were counted and plated in Dulbecco's Modified
Eagle's Medium-high glucose (DME-HG) (Irvine Scientific, Santa Ana, CA) without serum, at 1.4. 106/ml per
well or 5.6- 105/0.2 ml per well in 48-well or 96-well
plates, respectively. It was assumed that approximately
5-10% of the cells plated would be recovered as
macrophages. The cells were allowed to adhere overnight,
after which the wells were washed and the medium was
replaced with DME-HG supplemented with 20% ( v / v )
heat-inactivated fetal bovine serum (FBS) (Sigma, St.
Louis, MO), 10% ( v / v ) human AB serum (Advanced
Biotechnologies, Columbia, MD), penicillin (100 U/ml),
streptomycin (100 ~zg/ml) and L-glutamine (4 mM). The
cells were left undisturbed in this medium for 5 - 6 days, by
which time differentiation occurred. Macrophages were
then maintained at 37°C, under 5% CO 2 in D M E / 2 0
(DME-HG + 20% heat-inactivated FBS) medium supplemented with penicillin (100 U/ml), streptomycin (100
txg/ml) and L-glutamine (4 mM). Every 2 days the medium
was removed completely and replaced with fresh medium.
Infection of macrophages was performed 8 days postisolation. The virus and infected cells were handled in a
BL-3 facility. A monocytotropic strain of HIV-I, recovered from primary lung cultures and designated HIV-1BaL
[30], was used in these experiments. Cells were exposed to
the virus for 2 h at 37°C; then the medium was removed
and the cells were washed three times to remove unbound
virus. After infection macrophages were cultured for an
additional 12 days in fresh D M E / 2 0 medium, l ml/well
or 0.25 ml/well in 48-well or 96-well plates, respectively,
with medium changes 3 times/wk. The progress of infection was monitored by determining viral p24 in culture
supernatants, by an antigen capture ELISA assay described
previously [38], using a Molecular Devices (Menlo Park,
CA) Vmax microplate reader.
Viral inocula were standardized by their p24 content,
and cultures were infected at a concentration of 5 or 1.4 ng
p24 per well in 48-well or 96-well plates, respectively.
HIV-1Ba L obtained from Advanced Biotechnologies Inc.
(Columbia, MD) was propagated in macrophages, harvested at times of peak p24 production and stored in 1 ml
aliquots at - 80°C. The reverse transcriptase activity of the
virus stock solution was 8.3. 1 0 3 cpm/ml, and the p24
concentration was 50 ng/ml.
THP-1 cells were obtained from the American Type
Culture Collection (TIB-202). A chronically HIV-infected
cell line (designated THP-I/HIV-1 nIB) was developed in
our laboratory by infecting THP-1 cells with HIV-I nm at a
low multiplicity of infection [39]. THP-1/HIV-lmB cells
were cloned by limiting dilution in flat-bottom 96-well
plates. After 50 and 71 days in culture, supernatants were
screened for HIV production, and it was found that 29 of
30 clones obtained (96.7%) were positive for p24 production. Subsequently, samples of all clones were treated with
160 nM phorbol 12-myristate 13-acetate (PMA), for 24 h
at 37°C, to check for differentiation. Fifteen of the clones

adhered strongly after PMA treatment and produced virus.
These clones were expanded and cryopreserved. The clone
designated as THP-1/ina30 was used in further experiments. Cells were maintained at 37°C, under 5% CO 2 in
RPMI 1640 medium supplemented with 10% ( v / v ) heatinactivated FBS (RPMI/10), penicillin (100 U/ml),
streptomycin (100 I~g/ml) and L-glutamine (2 raM). The
cells were passaged 1:6 once a week.
2.3. Exposure o f cells to cationic liposomes

HIV-1BaL-infected macrophages were treated with liposomes in the presence of 20% FBS, on day 12 post-infection. Uninfected macrophages were treated with liposomes
on day 11 post-isolation. Uninfected monocytic THP-1
cells and chronically infected THP-1/HIV-IlI m cells (1 ml
at l • l 0 6 cells/ml) were plated in 48-well plates, treated
with 160 nM PMA for 24 h at 37°C and exposed to
liposomes in the presence of 10% FBS, 6 or 7 days
post-differentiation. Infection of THP-1/HIV-1 mB cells
was monitored by the p24 level in supernatants, p24 values
represent the amount of virus produced (in ng/ml) between the time of medium change and time of sampling
for p24. This time period is indicated in the Figure legends
for each experiment.
The cells were exposed to Lipofectamine at 3 or 8 IxM,
and to Lipofectin and DMRIE at 15 or 40 IxM, for 4 h or
24 h at 37°C; the medium with liposomes was then removed and fresh medium was added. Lipofectamine, the
formulation containing the lipid DOSPA (carrying a spermine headgroup) with a charge of + 5 at neutral pH, was
used at concentrations recommended by the manufacturer's
protocol (Lipofectamine at 25 p,1/ml is equivalent to 12.5
p,M lipid). The monocationic liposomal preparations,
Lipofectin and DMRIE, were used at concentrations of 15
p,M, which is equivalent to the highest recommended
concentration (Lipofectin and DMRIE at 20 ixl/ml are
equivalent to 13.7 p,M and 15 IxM lipid, respectively), and
40 p~M, to obtain a higher positive charge concentration,
slightly less than that of 3 o,M Lipofectamine. To achieve
the number of positive charges equivalent to that for 8 )xM
Lipofectamine, both Lipofectin and DMRIE would have to
be used at concentrations of 120 IxM ( ~ 170 Ixl/ml),
which is above the toxic level. Following treatment with
liposomes, cells were cultured and fed every 2-3 days
with fresh medium (DME/20 for macrophages and
RPMI/10 for THP-1 cells). Control cells were treated
similarly with the equivalent amount of appropriate medium
but not exposed to liposomes. Liposome-related toxicity
was evaluated by the Alamar Blue assay and p24 production.
2.4. Cell viability assays

Cell morphology before and after treatment with liposomes was evaluated by inverted phase contrast mi-
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croscopy at 25 × magnification. The number of viable
cells in suspension used for experiments was determined
by Trypan Blue exclusion.
Both macrophages and differentiated THP-1 cells that
do not multiply after PMA-treatment adhere to the plastic,
and accurate counting of adherent cells is difficult. Direct
counting is often unsatisfactory, since it is difficult to
select truly representative microscopic fields. To overcome
this problem we quantified cell viability after treatment
with liposomes using a modified Alamar Blue assay [40].
The Alamar Blue assay was recently introduced by Alamar
Biosciences (Sacramento, CA) as an indicator of cell viability allowing continuous monitoring of cell proliferation
a n d / o r cytotoxicity [40]. This colorimetric assay measures
the oxido-reductive capacity of cells due to the production
of metabolites, as a result of cell growth, and permits
determination of viability over the culture period without
the detachment of adherent cells. The non-toxic Alamar
Blue dye can be washed off and the culture continued
without termination of the experiment. This assay has been
applied to determine the proliferation of lymphocytes [41],
and the adhesion rate and viability of monocytes and
macrophages [42]. Briefly, 1.0 ml of appropriate medium
and 0.1 ml of Alamar Blue, or 0.2 ml of medium and 20
ILl of Alamar Blue, was added to 48-well or 96-well
culture plates, respectively. After incubation for various
times (described under Figure legends) at 37°C, 200 p,1 of
the supernatant was collected from each well and transferred to 96-well plates. The absorbance at 570 nm and
600 nm was measured using a Molecular Devices Vn~x
microplate reader. Cell viability (as a percentage of mocktreated control cells) was calculated according to the formula, (A570 A600) of test cells × 100/(A570 At00) of
control cells. After removal of the Alamar Blue/medium
mixture, fresh growth medium was added and the cells
were returned to the incubator.
The results obtained by the Alamar Blue assay were
-

-

-

-
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correlated with two indirect methods: Trypan Blue exclusion and nuclear counting [43]. Adherent cells were detached, using the enzyme-free dissociation buffer, and
counted by the Trypan Blue exclusion method. For nuclear
staining, adherent cells were washed with PBS and treated
with 0.1 ml of the counting solution, I% ( w / v ) Triton
X-100 in 0.1 M citric acid with 0.05% ( w / v ) naphtol blue
black, pH 2.2. After 30 min incubation at room temperature the solution was mixed and the suspension of fixed
stained nuclei was counted in a hemocytometer.

3. Results

3.1. Effect of liposomes on uninfected macrophages
Uninfected macrophages were treated with the cationic
liposomes for 24 h, and cell viability was quantified by the
Alamar Blue assay on days 7, 9, 11 and 15 after treatment.
Lipofectamine and Lipofectin were not toxic at the concentration range tested. The toxic effect of DMRIE was very
limited, and a decrease in cell viability by ~ 20% could be
observed after 15 days (Fig. 1). A 4 h treatment of
uninfected macrophages with the cationic liposomes was
not toxic, even up to 15 days post-treatment (data not
shown).

3.2. Effect of liposomes on chronically infected
macrophages
Chronic HIV-1 infection is usually established in infected macrophages 10-12 days after virus challenge, as
determined by stabilization of both the number of HIV
antigen-expressing cells detected by immunofluorescence
and proviral DNA determined by the polymerase chain
reaction [44]. We treated HIV-1B~L-infected macrophages
with the cationic liposomes on day 12 post-infection, when
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Fig. 1. Effect of cationic liposomeson viabilityof uninfected macrophages.Macrophagesin 96-well plates were exposedto the cationic liposomes(LipA:
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chronic infection was already established. Infection of
macrophages reduced cell viability by about 50% (data not
shown). We also determined p24 production in chronically
infected macrophages before treatment with the cationic
liposomes. Only wells exhibiting similar cell viability and
p24 production were exposed to the cationic liposomes;
this procedure allowed us to avoid inter-experiment variability caused by differences both in initial infection and
its progression.
HIV-1BaL-infected macrophages were treated with the
cationic liposomes for 4 h; cell viability was quantified on
days 6 and 13, and p24 production was measured on days
7 and 14 after treatment. After a 24 h treatment, cell
viability and p24 production were determined on days 6
and 14 after treatment. Neither Lipofectamine nor Lipofectin was toxic after a 4 h treatment, while a decrease in
cell viability by ~ 50% could be observed with DMRIE at
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Fig. 2. Effect of cationic liposomes on viability of HIV-1BaL-infected
macrophages. (A) Macrophages in 48-well plates, were exposed to the
cationic liposomes (LipA: Lipofectamine. Lipof: Lipofectin) for 4 h as
described in Section 2. Cell viability was measured by the Alamar Blue
assay on days 6 and 13 (incubation for 2.5-4 h at 37°C) and was
expressed as percent of the control. (B) Macrophages in 96-well plates
were exposed to the cationic liposomes for 24 h. Cell viability was
measured on days 6 and 14 (incubation for 2.5 h or overnight at 37°C)
and was expressed as percent of the control. Data represent the mean + SD
obtained from triplicate wells or 6-8 control wells.
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Fig. 3. Effect of cationic liposomes on p24 production in HIV-IB~L-infected macrophages. (A) Macrophages in 48-well plates were exposed to
the cationic liposomes (LipA: Lipofectamine. Lipof: Lipofectin) for 4 h
as described in Section 2. The p24 antigen production within a 24 h
period was determined in cell culture supernatants on days 6 and 13 after
treatment and was expressed as percent of the control (100%: 20.9_+ 1.8
and 9.1 _+ 1.8 ng p24/ml on days 6 and 13, respectively). Data represent
the mean _+standard deviation of p24 determinations in duplicate, in
supernatants of triplicate wells (n = 6) or 6 control wells (n = 12). (B)
Macrophages in 96-well plates were exposed to the cationic liposomes for
24 h. A 48-h production of p24 antigen was determined in cell culture
supernatants on days 6 and 14 after treatment and was expressed as
percent of the control (100%: 101.0_+ 13.6 and 20.1 _+3.6 ng p24/ml on
days 6 and 14, respectively). Data represent the m e a n + S D of p24
determination in duplicate, in supernatants of triplicate wells (n = 6) or 8
control wells (n = 16).

40 ~ M (Fig. 2A). A 24 h exposure to Lipofectin at 15 or
40 IxM reduced cell viability by ~ 20% and 30%, respectively (Fig. 2B). At the same concentrations, DMRIE
caused greater cytotoxicity, reducing cell viability by ~
40% and 70% at 15 and 40 ~M, respectively. Lipofectamine was not toxic after a 24 h treatment. Similar results
were obtained when the effects of cationic liposomes were
determined by measuring p24 levels in the harvested supernatant (Fig. 3). However, there were some differences
between the viability assay and p24 production. For example, while no detectable cytotoxicity was observed at 15
ixM DMRIE after a 4 h treatment (Fig. 2A), the production
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of p24 antigen in the culture supernatant was inhibited by
~ 30% (Fig. 3A)

3.3. Effect of liposomes on differentiated uninfected THP-1
cells
PMA-treated THP-1 cells were exposed to the cationic
liposomes for 24 h, and cell viability was quantified on
days 6, 9, and 13 after treatment (Fig. 4). While Lipofectamine at 3 and 8 txM and Lipofectin at 15 IxM were not
toxic, 40 IxM Lipofectin caused a reduction in cell viability by ~ 4 0 % on days 6 and 9, and by 70% on day 13.
Although the toxic effect of DMRIE was limited, a decrease in cell viability by 30-40% could be observed after
13 days at both concentrations (Fig. 4),

3.4. Effect of liposomes on differentiated THP-1/ HIV-lm8
cells
Differentiated THP- 1/HIV- 1111Bcells were treated with
the cationic liposomes for 4 h; cell viability was quantified
on days 5 and 14, and p24 production was measured on
days 5, 8 and 14 after treatment. A 4 h exposure to any of
the three liposomes did not reduce cell viability and p24
production even up to 14 days post-treatment (data not
shown). Following a 24 h treatment of these cells, cell
viability was determined on day 1, 8 and 12, and p24
production was measured on days 3, 7 and 12 after the end
of the treatment period. At the lower concentration, none
of the three liposomes reduced cell viability after a 24 h
treatment as measured by the Alamar Blue assay (Fig. 5A).
However, Lipofectin and DMRIE at 15 ~M inhibited viral
p24 production measured on days 7 and 12 after treatment
by ~ 40% (Fig. 5B), although they did not show an effect
on day 3. All three cationic liposomes were toxic at the
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higher concentration after a 24 h treatment (Fig. 5A,B).
Interestingly, concentrations of liposomes that were not
toxic at early time points subsequent to treatment could
cause significant toxicity at later times. For example, p24
production was not affected by 40 p,M Lipofectin or
DMRIE on day 3, while on days 7 and 12 it was reduced
by ~ 80% (Fig. 5B).

3.5. Comparison of the Alamar Blue assay with the Trypan
Blue exclusion and the nuclear counting methods
PMA-treated THP- 1 and THP- 1/HIV- 1nm cells were
exposed to the cationic liposomes for 24 h. On day 9 after
treatment, the Alamar Blue assay was performed, and cell
numbers were detemined by counting. DMRIE at 15 and
40 p~M was not toxic for differentiated uninfected THP-1
cells, while a 24 h exposure to Lipofectin at 40 ixM
reduced cell viability by ~ 50% (Fig. 6A). Lipofectin at
40 p~M and DMRIE at 15 and 40 IxM reduced the viability
of differentiated THP-1/HIV-1In B cells by ~ 50%, 60%
and 90%, respectively (Fig. 6B). After removal of the
Alamar Blue/medium mixture the cells were quantified by
the Trypan Blue assay and the nuclear staining method. In
the Trypan Blue assay only live cells were counted because the affected cells were disintegrating to such an
extent that very few cells took up and retained the Trypan
Blue. The results were consistent with phase contrast
microscopic observations (described below) that the cytotoxic effect was caused by significant damage of the cells
and not by mere changes in cell membrane permeability.
The viability of control mock-treated cells was 91-96%;
however, the absolute number of cells was only 10% of the
initially plated 106 cells/well. Thus, during the course of
the experiment, approximately 90% of cells were detached
and lost. The number of viable cells quantified in the
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Fig. 4. Effect of cationic liposomes on viability of differentiated uninfected THP-I cells. PMA-treated THP-I cells in 48-well plates were exposed to the
cationic liposomes (LipA: Lipofectamine. Lipof: Lipofectin) for 24 h, 7 days post-differentiation, as described in Section 2. Cell viability was measured on
days 6, 9, and 13 (incubation overnight at 37°C) and was expressed as percent of the control. Data represent the mean + SD obtained from duplicate wells
or triplicate control wells.
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Trypan Blue assay corresponded very well to the number
of nuclei stained with the naphtol blue black dye. For
example, the number of viable THP-1/HIV-1Hm cells and
their nuclei, counted in duplicate control wells with the
Trypan Blue or naphtol blue black methods, was 1.24 ___
0.07 • 105 and 1.07 ___0.03 • 105, respectively.
When expressed as a percentage of controls, both the
Trypan Blue exclusion and the nuclear counting methods
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Fig. 5. Effect of cationic liposomes on viability and p24 production in
differentiated T H P - I / H I V - l n m cells. PMA-treated T H P - 1 / H I V - l m a
cells in 48-well plates were exposed to the cationic liposomes (LipA:
Lipofectamine. Lipof: Lipofectin) for 24 h, 6 days post-differentiation, as
described in Section 2. (A) Cell viability was measured on days 1, 8, and
12 (incubation overnight with Alamar Blue at 37°C) and was expressed as
percent of the control. Data represent the mean+standard deviation
obtained from duplicate wells or triplicate control wells. (B) The p24
antigen production within the previous 48 h period was determined in cell
culture supernatants on days 3 and 7; on day 12, p24 production within
the previous 72 h was measured. The values were expressed as percent of
the control (100%: 7.9+0.9, 15.1___2.5 and 13.1-1-1.4 ng p 2 4 / m l on
days 3, 7 and 12, respectively). Data represent the mean+standard
deviation of p24 determination in duplicate, in supernatants of duplicate
wells (n = 4) or triplicate control wells (n = 6).
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Fig. 6. Effect of cationic liposomes on the viability of differentiated
THP-1 and THP-1/HIV-Ium cells-comparison of the Alamar Blue assay
with Trypan Blue exclusion and the nuclear counting methods. PMAtreated THP-1 and THP-1/HIV-11nB cells in 48-well plates were exposed
to the cationic liposomes (Lipof: Lipofectin) for 24 h, 6 days post-differentiation, as described in Section 2 (4 wells/condition). On day 9
post-treatment, cell viability was measured by the Alamar Blue assay
(incubation for 3 h and 20 min at 37°C) and was expressed as percent of
the control. After removal of the Alamar Blue/medium mixture, the
number of viable cells or their nuclei were counted with the Trypan Blue
or naphtol blue black methods, respectively, and expressed as the percentage of the control. Data represent the mean + SD obtained from quadruplicate wells (Alamar Blue) or duplicate wells (Trypan Blue or naphtol
blue black). (A) THP-1 cells; Alamar Blue assay, 100%: A570 - A600 =
0.39; Trypan Blue assay, 100%: 1.04-105 cells; naphtol blue black,
100%: 1.02.105 cells. (B) THP-1/HIV-lmB cells; Alamar Blue assay,
100%: A570 - A600 = 0.334; Trypan Blue assay, 100%: 1.24.105 cells;
naphtol blue black, 100%: 1.07.105 cells.

gave results similar to that obtained with the Alamar Blue
assay (Fig. 6A and B). Variation in the results was found
only in the case of THP-1/HIV-lnI B cells treated with 40
IxM DMRIE, where a very significant cytotoxic effect was
observed. The trend in the toxic effect of the cationic
liposomes was similar to that presented in Figs. 4 and 5A,
although some inter-experiment variations were observed.
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Fig. 7. Effect of cationic liposomes on the morphology of differentiated uninfected THP-1 cells. PMA-treated THP-1 cells in 48-well plates were exposed
to the cationic liposomes for 24 h, 7 days post-differentiation, as described in Section 2. Phase contrast micrographs were taken 3 days after treatment
(magnification: 400 × ). Frame a shows untreated cells. Frames b - f show cells treated with 8 I.LM Lipofectamine (b), 15 ~ M Lipofectin (c), 40 ixM
Lipofectin, 15 $xM DMRIE (e), and 40 p,M DMRIE (f).
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3.6. Cell m o r p h o l o g y

Cell morphology can be a sensitive indicator of the
toxicity of certain compounds. PMA-treated THP-1 cells
were exposed to the cationic liposomes for 24 h, and
micrographs were taken 3 days after treatment in the same
experiment whose results are shown in Fig. 4. Lipofectamine, at the concentrations used in our studies, had no
significant effect on the morphology of differentiated
THP-1 cells compared to untreated control cells (Fig. 7b).
40 p~M Lipofectin was highly cytotoxic, causing disintegration of cells (Fig. 7d). Changes of cell morphology
were also seen with 40 ixM DMRIE (Fig. 70.

4. Discussion

In this study, we investigated the toxicity of one polycationic (Lipofectamine) and two monocationic (Lipofectin
and DMRIE) liposomal preparations to uninfected and
HIV-infected cells. Our results demonstrate that (i)
macrophages and PMA-treated THP- 1 or THP- 1/HIV- 1nlB
cells differ in their sensitivity to the toxic effect of cationic
liposomes; (ii) HIV-infected cells are more susceptible to
killing by cationic liposomes than uninfected cells; (iii)
concentrations of liposomes that were not toxic at early
time points subsequent to treatment could cause toxicity at
later times; (iv) in infected cells, virus production is more
sensitive to the effects of cationic liposomes than the
overall viability of the cells as measured by a metabolic
assay.
Chronically HIV-1-infected macrophages and differentiated THP-1/HIV-lnm cells were selected in our study
because of the importance of macrophages in the pathogenesis and progression of HIV infection [32,33]. The avid
endocytosis of liposomes by mononuclear phagocytes [4547] should promote cationic lipid-mediated transfection of
therapeutic genes and delivery of anti-HIV anti-sense
oligodeoxyribonucleotides or ribozymes via the endocytotic pathway.
Both cationic lipids alone and lipid-DNA complexes
show various levels of growth inhibition and toxicity to
cells, depending on the cell type and the confluency of the
cell culture [3,8,22,48-50]. The molecular and cellular
basis of this variability is not known. Generally, transfected cells are temporarily growth-arrested or grow more
slowly than untransfected cells [51]. In our study,
macrophages and differentiated THP-1 cells were exposed
to liposomes in the presence of 20% or 10% FBS, respectively. Although earlier reports on lipofection emphasized
the use of serum-free conditions, recent studies indicate
that successful transfections with cationic liposomes can
be achieved in the presence of serum, provided that the
lipid-DNA complexes are prepared under serum-free conditions. The presence of serum can also diminish the

growth inhibition a n d / o r toxic effects associated with
lipofection [52,53].
Two questions raised by our findings are (i) why differentiated THP-1 and THP-I/HIV-1 mB cells were more
sensitive than macrophages to the toxic effect of cationic
liposomes, and (ii) why THP-1 cells were more sensitive
to Lipofectin (Fig. 4), while DMRIE was more toxic to
macrophages (Fig. 2). The established human monocytoid
cell lines have been used to study HIV-monocyte/macrophage interactions, the relationship between virus production and cell differentiation, and virus latency [54-56].
Compared to other monocytoid cell lines, differentiated
THP-1 cells behave more like native monocyte-derived
macrophages [57]. More than 80% of the PMA-treated
THP-1 cells change morphologically and adhere to the
substratum; 60 to 70% of these cells are able to phagocytose yeast particles and immunoglobulin G-coated erythrocytes [58]. PMA-treated THP- 1/HIV- lttm cells represent a
convenient model of HIV-1 production in differentiated
cells [39]. The monocytoid cells are a useful tool for
studying specific aspects of virus-cell interactions; however, none of these cell lines properly represents monocyte/macrophages. The capacity of HIV-1 isolates to
replicate in established monocytoid cell lines does not
correlate with the tropism of the virus for primary
mononuclear phagocytes [56,59]. HIV-1BaL does not replicate in any of the monocytoid cell lines in spite of high
CD4 expression in some of the lines, and both the expression of cell surface markers and cytokine production vary
significantly among these cell lines. For example, the
monocytic marker CD14 is expressed in few THP-I cells
(4%), but in a majority of blood monocytes (97%) [59].
Thus, the different sensitivity of macrophages and THP-I
cells to cationic liposomes may be related to the differences in the intrinsic properties of the cells. The structural
characteristics of the different lipids may also determine
how they interact with the different cell surface components on these two cell types. Interestingly, the formation
of complexes between cationic liposomes and RNA significantly changed the toxic effect of liposomes [60]. A 4-h
treatment of differentiated THP-1 cells with the Lipofectamine/ribozyme complex at 8 p~M lipid caused a decrease in cell viability by ~ 80% [60], while 8 IxM
Lipofectamine alone was not toxic even after a 24-h
treatment (Fig. 4). In contrast, a 24-h treatment with the
Lipofectin/ribozyme complex at 40 lxM lipid was not
toxic, while with 40 p~M Lipofectin alone cell viability
was significantly reduced (Fig. 4). Incubation of endothelial cells for 4 h with 24 IxM (or greater) Lipofectin in the
presence of antisense oligonucleotides in serum-free
medium (followed by overnight incubation in serum-containing medium without the cationic lipids) was toxic to
these cells, as determined by the loss of adherent cells at
the end of this incubation period [29].
Another question raised by our results is why chronically HIV-l-infected cells are killed more effectively by
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cationic liposomes than are uninfected cells. The interaction of cationic liposomes with cells involves surface
binding and internalization, and it is unclear which cellular
component(s) are involved in these processes. The effects
of HIV infection on monokine production and metabolic
and immune functions of macrophages, both in vivo and in
vitro, are not well defined [33,34]. It is possible that the
continuous production (budding) of the virus and expression of viral envelope proteins can alter the susceptibility
of the cell membrane in HIV-infected cells to interaction
with cationic liposomes. Our results indicate that cells with
relatively high overall viability could be impaired in their
ability to produce virions. Thus, virus production appears
to be more sensitive to treatment with the cationic liposomes than cell viability measured by the Alamar Blue
assay. This observation suggests that cationic liposomes,
by inserting into intracellular membranes, may affect the
transport of viral components to the cell surface and virus
budding. Cytoplasmic vesicles in epithelial cells in which
antisense oligonucleotide/Lipofectin complexes accumulate appear to be larger than those in which the oligonucleotide alone accumulates [29]. One interpretation that
has been offered for this observation is that the lipid
promotes fusion of smaller cytoplasmic vesicles [29].
Our results indicate that cationic liposomes can have
prolonged effects on cells after the initial incubation period. Although cationic liposomes may appear to have no
cytotoxicity within a few days after treatment, they may
become toxic later. It is therefore important to monitor
cytotoxicity for relatively long time periods. This delayed
cytotoxicity may be related to the stability of the cationic
lipids used in this study, and the inability of the cells to
metabolize them. In this respect it will be of interest to
compare the toxic effect of these lipids which contain ether
bonded alkyl chains to liposomes containing (N[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP), which has ester bonded acyl chains [20,22].
It is interesting to note that Lipofectamine is less toxic
than Lipofectin in the cellular systems tested, even at
higher concentrations of the cationic lipid component and
a higher number of charges per DOSPA molecule. For
example, 8 p~M Lipofectamine reagent corresponds to 24
p~M DOSPA, equivalent to 120 I~M in cations, while 15
~M Lipofectin corresponds to 15 IxM DOTMA, equivalent to the same concentration of cations. This observation
indicates that the concentration of positive charge per se is
not a determinant of toxicity. Cytotoxicity is more likely to
be linked to the structure of the cationic molecule as well
as its ability to be metabolized by the cell.
Our observations point to the importance of evaluating
lipid-dependent effects on virus replication when the therapeutic effects of antisense oligonucleotides, ribozymes or
genes delivered by cationic liposomes are being investigated. Although this study has concentrated on the toxic
effects of pure lipids, the toxicity of nucleic acid/cationic
liposome complexes needs to be examined just as thor-
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oughly when evaluating the sequence-dependent effects of
therapeutic nucleic acids on virus production or cell proliferation.
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